Association of transforming growth factor alpha polymorphisms with nonsyndromic cleft lip and palate in Iranian population.
Background: Cleft lip with or without cleft palate (CL/P) is one of the most common congenital anomalies and the etiology of orofacial clefts is multifactorial. Transforming growth factor alpha (TGFA) is expressed at the medial edge epithelium of fusing palatal shelves during craniofacial development. In this study, the association of two important TGFA gene polymorphisms, BamHI (rs11466297) and Rsal (rs3732248), with CL/P was evaluated in an Iranian population.
Methods: The frequencies of BamHI and Rsal variations were determined in 105 unrelated Iranian subjects with nonsyndromic CL/P and 218 control subjects using PCR and RFLP methods, and the results were compared with healthy controls. A p-value of <0.05 was considered statistically significant.
Results: The BamHI AC genotype was significantly higher (p=0.016) in the patients (12.4%) than the control group (5.0%). The BamHI C allele was significantly higher (p=0.001; OR=3.4, 95% CI: 1.6-7.4) in the cases (8.0%) compared with the control group (2.5%).
Conclusion: Our study showed that there was an association between the TGFA BamHI variation and nonsyndromic CL/P in Iranian population.
Keywords: Association Study, Cleft lip/palate. Polymorphism, Transforming Growth Factor Alpha
Cleft lip with or without cleft palate (CL/P) is one of the most common birth defects (1). The worldwide prevalence of CL and CL/P is 3.28 and 6.64 per 10.000 cases, respectively (2-4). Genetic factors are thought to contribute to the development of this disorder, because the risk of recurrence of CL/P within a family is approximately 28-40-fold greater for the general population (5,6). Nonsyndromic cleft in humans is most likely due to combination of genetic and environmental factors (7,8). Population based candidate gene studies as well as linkage disequilibrium has been used to identify the etiology of CL/P so as to predict its occurrence and to prevent it from occurring in the future. Identification of the genes involved in the development of the human craniofacial region can serve as a first step towards developing a better understanding of the diagnosis, prevention and treatment of developmental anomalies of this region (9,10).
The association between CL/P and specific alleles in the transforming growth factor alpha (TGFA) gene suggests that TGFA could be a candidate gene for CL/P (11-15)
In 1989, Ardinger et al published the first association study of CL/P with five candidate genes which were involved in palate formation. Analysis of 80 unrelated patients from Iowa showed that there were significant associations of CL/P with TaqI and BamHI RFLPs at the TGFA locus (34). Holder et al in a British population (24), Tanabe et al in a Japanese population (30) and Stoll et al in the French population (25) indicated that the TGFA gene variant contributes to the occurrence of nonsyndromic CL/P. However, this is contrary to a study done by Lidral et al in the Philippines (36), which may be due to genetic differences in different populations.
TGFA is, both structurally and functionally, similar to Epidermal Growth Factor (EGF), and induces a mitogenic response by binding to and stimulating the tyrosine kinase activity of EGF receptor (16,17). During craniofacial development, TGFA is expressed at the medial edge epithelium of fusing palatal shelves (18,19). In palatal cultures, TGFA promotes synthesis of extra-cellular matrix and migration of mesenchymal cells to ensure the strength of the fused palate during seam disruption (20-24).
The TGFA gene is located on chromosome 2p13 (11), contains six exons and spans 80 kb of genomic DNA. Three common polymorphisms of the TNFA gene (RsaI, and TaqI in intron 5 and BamHI in exon 6) have been investigated with susceptibility to the CL/P (25-27). The results of the association studies of TGFA gene polymorphisms and the risk of nonsyndromic CL/P have been contradictory and conflicting (28-31). The aim of the present study was to investigate the association of the two common polymorphisms of the TGFA gene, BamHI and RsaI, in the development of nonsyndromic CL/P in an Iranian population for the first time.
Materials and Methods
To determine the possible role of BamHI and RsaI polymorphisms in the TGFA gene in developing oral clefts in an Iranian population, a case-control study was performed. A sample of 105 newborns with nonsyndromic CL/P and 218 control subjects were included. A clinical examination to look for dysmorphic features (such as lip pits) was undertaken. The exclusion criteria of this study were evidence of other facial or skeletal malformations (such as lip pits, congenital heart lesion, etc), metabolic or neurologic disorders or anomalies of other organ systems. Samples were recruited from Mofid Hospital, a referral pediatrics center in Tehran, Iran in 2013-15. A control group consisted of 218 Iranian newborns, without cleft, who were born in or around Tehran between the years 2013 and 2015 were selected and their blood samples were stored. Ethical approval for the study was obtained from the Ethics Committee of the Dental Research Center of the University of Shahid Beheshti. Informed consent was obtained from all parents.
DNA extraction and genotyping
Five ml of peripheral blood samples were collected in tubes containing 200 [micro]l 0.5 M EDTA and genomic DNA was extracted from peripheral blood using the salting out method (32). Genotyping of the BamHI (rs11466297) and RsaI (rs3732248) polymorphisms in the TGFA gene was performed by polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) methods, according to the previous study. The primer sequences are shown in table 1. Briefly, a total volume of 25 [micro]l containing 30 ng of genomic DNA, 10 pmol of each primer, 1 [micro]l dNTPs mix (Fermentas, Life Science), 2.5 [micro]l 10 x buffer and 0.5 U of Taq DNA polymerase (Fermentas Life Science, Lithuania) with 1.5 mM Mg[Cl.sub.2] was prepared in the 0.5 ml Eppendorf microtube for amplification of the target sequences. Amplification conditions started with an initial denaturation step of 4 min at 95[degrees]C, followed by 33 cycles of 45 s denaturation (94[degrees]C), 30 s annealing (60 [degrees]Q and 40 s extension (72 [degrees]Q, ended by a final extension for 5 min (72[degrees]C) and finally cooling to 4[degrees]C. The PCR products of the rs11466297 and rs3732248 polymorphisms were digested with the IU BamHI and RsaI restriction enzymes at 37[degrees]C overnight, respectively (New England BioLabs, Beverly, MA, USA). All PCR products were subjected to 8% polyacrylamide gel electrophoresis and stained with silver nitrate. The pattern of restriction fragments for both BamHI and RsaI are shown in table 1.
Chi square ([chi square] and Fisher's exact test with Open Epi Version 2.2 (free statistical software) were performed to compare genotype and allele frequencies in the study groups. The p<0.05 were considered statistically significant. Statistical significance was corrected for multiple testing comparisons.
The samples consisted of 105 patients with cleft lip with or without cleft palate and 218 healthy controls. The CL/P samples consisted of 65 males (62.0%) and 40 females (38.0%). A positive family history of cleft was observed in 38 CL/P cases (36.19%). There were 34 (32.3%) patients with unilateral CL/P, 27 (25.7%) with bilateral CL/P, 15(14.2 %) cleft lip only and 29 (27.6%) with cleft palate only. The distributions of genotypes using chi-square showed that in both case and control groups, for the TGFA BamHI polymorphism, they were in Hardy-Weinberg equilibrium (p>0.05). For the TGFA RsaI polymorphism, the distributions of genotypes in the case group were in Hardy-Weinberg equilibrium (p=0.625). The genotype distributions and allele frequencies of the TGFA BamHI and RsaI polymorphisms are shown in table 2. The results of the genotyping for the BamHI and RsaI RFLP are shown in figures 1 and 2. Our results showed that there was a significant difference in the genotype distribution and allele frequency of the BamHI polymorphism between the case and control groups. The BamHI AC genotype was significantly higher (p=0.016; OR=2.1, 95% CI:1.2-6.3) in the patients (12.4%) than the control group (5.0%). The BamHI C allele was significantly higher (p=0.001; OR=3.4, 95% 0:1.6-7.4) in the cases (8.0%) compared with the control group (2.5%). In contrast, no significant difference in the genotype and allele frequencies of the RsaI polymorphism was found between the case and control groups.
TGFA was chosen as a candidate gene in the preliminary association studies of CL/P, because it is expressed in palatal tissue in culture (16,30). It subsequently revealed that TGFA was present at high levels in epithelial tissue of the medial edge of the palatal shelves at the time of shelf fusion (17). The role of TGFA in lip and palate development was then evaluated in different populations.
This study was performed to examine whether the TGFA BamHI (rsl 1466297 A/C) and RsaI (rs3732248 C/T) variations are associated with the increased risk of CL/P in an Iranian population including 105 CL/P patients and 218 controls. Our results showed that TGFA BamHI polymorphism was associated with the CL/P in Iranian population. The frequency of the BamHI AC genotype in the patients (12.4%) was approximately twice more than that of control group (5.0%). The BamHI C allele was significantly higher in the CL/P patients (8.0%) compared with the control group (2.5%). This result suggests that the C allele may be a risk factor for CL/P in Iranian population. In contrast, no significant difference in the genotype and allele frequencies of the RsaI polymorphism was found between the case and control groups. The minor allele frequencies in the control groups, for the BamHI and RsaI polymorphisms were C=0.025 and A=0.260, respectively, which are very close to the global minor allele frequencies (0.024 and 0.208, respectively).
Ardinger et al (1989) investigated the possible association of five candidate genes including TGFA, Nuclear Receptor subfamily 3 group C member 1 (NR3CI), Epidermal Growth Factor (EGF), Epidermal Growth Factor Receptor (EGFR) and estrogen receptor (ESR) in an American population with nonsyndromic CL/P. They found a significant association between the TGFA BamHI and TaqI polymorphisms and the occurrence of cleft. Their results suggest that TGFA gene or adjacent DNA sequences may contribute to the development of a portion of cases with CL/P (33). Holder et al (1992) studied the three variations of TGFA (BamHI, TaqI and RsaI) in a British population with CL/P, and they found a significant association between the TaqI polymorphism and occurrence of cleft ~4. Stoll et al (1992) detected a significant association with BamHI and not with TaqI in a French population of Alsatian ancestry with CL/P. They concluded that TGFA may be a modifier gene, not a major gene that may play a role in the development of bilateral cleft in some individuals (25). Chenevix-Trench et a! (1992) studied the two polymorphisms of TGFA in unrelated Australians with CL/P and a significant association between the TGFA TaqI and BamHI polymorphism and CL/P was confirmed (34). Lidral et al (1997) evaluated the association of four candidate genes TGFA, TGFB2, TGFB3, homeobox 7 (MSX1) variations in a population from Philippines; however, no evidence for association of TGFA with nonsyndromic CL/P was found in non-Caucasian population (35). Tanabe et al (2000) assessed the association of polymorphisms of candidate genes TGFA, TGFB and gamma-aminobutyric acid type A receptor beta3 (GABRB3) with nonsyndromic CL/P in Japanese patients, and they found that the TGFA and TGFB2 polymorphisms were associated with CL/P (30).
In conclusion, our study showed that there was an association between the TGFA BamHI variation and nonsyndromic CL/P in Iranian population. Since common environmental exposures especially maternal smoking could play a role in the CL/P etiology, it is suggested that further works be done to explore the role of possible gene-environment interaction in the etiology of CL/P.
We would like to thank Dr Roozrokh (Dean of Mofid Hospital) and Mofid hospital staff for their kind helps in recruiting study subjects. Moreover, this study was carried out as a part of a master of sciences thesis in Shahid Behehsti University of Medical Sciences, Tehran, Iran and Genetic Research Centre, University of Social Welfare and Rehabilitation Sciences.
Conflict of Interest
The authors report no conflicts of interest.
(1.) Mijiti A, Ling W, Guli, Morning A. Association of single-nucleotide polymorphisms in the IRF6 gene with non-syndromic cleft lip with or without cleft palate in the Xinjiang Uyghur population. Br J Oral Maxillofac Surg 2015;53(3):268-274.
(2.) Niranjane PP, Kamble RH, Diagavane SP, Shrivastav SS, Batra P, Vasudevan SD, et al. Current status of presurgical infant orthopaedic treatment for cleft lip and palate patients: A critical review. Indian J Plast Surg 2014;47 (3):293-302.
(3.) Ranganathan K, Vercler CJ, Warschausky SA, MacEachern MP, Buchman SR, Waljee JF. Comparative effectiveness studies examining patient-reported outcomes among children with cleft lip and/or palate: a systematic review. Plast Reconstr Surg 2015;135(1):198-211.
(4.) Crockett DJ. Goudy SL. Cleft lip and palate. Facial Plast Surg Clin North Am 2014;22(4):573-586.
(5.) Aldhorae KA. Bohmer AC, Ludwig KU, Esmail AH. Al-Hebshi NN, Lippke B, et al. Nonsyndromic cleft lip with or without cleft palate in arab populations: genetic analysis of 15 risk loci in a novel case-control sample recruited in Yemen. Birth Defects Res A Clin Mol Teratol 2014; 100(4):307-313.
(6.) Rajabian MH, Sherkat M. An epidemiologic study of oral clefts in Iran: analysis of 1,669 cases. Cleft Palate Craniofac J 2000;37(2): 191-196.
(7.) Kalaskar R, Kalaskar A, Naqvi FS, Tawani GS, Walke DR. Prevalence and evaluation of environmental risk factors associated with cleft lip and palate in a central Indian population. Pediatr Dent 2013;35(3):279-283.
(8.) Ibarra-Lopez JJ. Duarte P, Antonio-Vejar V, Calderon-Aranda ES, Huerta-Beristain G, Flores-Alfaro E, et al. Maternal C677T MTHFR polymorphism and environmental factors are associated with cleft lip and palate in a Mexican population. J Investig Med 2013;61(6):1030-1035.
(9.) Grosen D. Chevrier C, Skytthe A, Bille C, Moisted K. Sivertsen A, et al. A cohort study of recurrence patterns among more than 54,000 relatives of oral cleft cases in Denmark: support for the multifactorial threshold model of inheritance. J Med Genet 2010:47(3):162-168.
(10.) Beaty TH, Taub MA, Scott AF, Murray JC, Marazita ML, Schwender H, et al. Confirming genes influencing risk to cleft lip with/without cleft palate in a case-parent trio study. Hum Genet 2013; 132(7):771-781.
(11.) Brissenden JE, Derynck R, Francke U. Mapping of transforming growth factor alpha gene on human chromosome 2 close to the breakpoint of the Burkitt's lymphoma t(2;8) variant translocation. Cancer Res 1985;45(11 Pt 2):5593-5597.
(12.) Tricoli JV, Nakai H, Byers MG, Rail LB, Bell GI, Shows TB. The gene for human transforming growth factor alpha is on the short arm of chromosome 2. Cytogenet Cell Genet 1986;42(1-2):94-98.
(13.) Nemo R. Murcia N, Dell KM. Transforming growth factor alpha (TGF-alpha) and other targets of tumor necrosis factor-alpha converting enzyme (TACE) in murine polycystic kidney disease. Pediatr Res 2005;57(5 Pt 1):732-737.
(14.) Mydlo JH, Michaeli J, Cordon-Cardo C, Goldenberg AS, Heston WD, Fair WR. Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res 1989:49(12):3407-3411.
(15.) Beaty TH. Hetmanski JB, Zeiger JS, Fan YT, Liang KY, VanderKolk CA. et al. Testing candidate genes for nonsyndromic oral clefts using a case-parent trio design. Genet Epidemiol 2002;22(1): 1-11.
(16.) Dixon MJ, Ferguson MW. The effects of epidermal growth factor, transforming growth factors alpha and beta and platelet-derived growth factor on murine palatal shelves in organ culture. Arch Oral Biol 1992;37(5):395-410.
(17.) Mossey PA, Little J, Munger RG, Dixon MJ, Shaw WC. Cleft lip and palate. Lancet 2009;374(9703): 1773-1785.
(18.) Mitchell LE. Transforming growth factor alpha locus and nonsyndromic cleft lip with or without cleft palate: a reappraisal. Genet Epidemiol 1997; 14(3):231-240.
(19.) Vieira AR, Orioli IM. Candidate genes for nonsyndromic cleft lip and palate. ASDC J Dent Child 2001;68(4):272-279.
(20.) Shiang R, Lidral AC, Ardinger HH, Buetow KH, Romitti PA, Munger RG, et al. Association of transforming growth-factor alpha gene polymorphisms with nonsyndromic cleft palate only (CPO). Am J Hum Genet 1993;53(4):836-843.
(21.) Machida J, Yoshiura Ki, Funkhauser CD, Natsume N. Kawai T, Murray JC. Transforming growth factor-alpha (TGFA): genomic structure, boundary sequences, and mutation analysis in nonsyndromic cleft lip/palate and cleft palate only. Genomics 1999:61 (3):237-242.
(22.) Qian JF, Feingold J, Stoll C, May E. Transforming growth factor-alpha: characterization of the BamHI, RsaI, and faql polymorphic regions. Am J Hum Genet 1993;53(1):168-175.
(23.) Vanderas AP. Incidence of cleft lip, cleft palate, and cleft lip and palate among races: a review. Cleft Palate J 1987; 24(3):216-225.
(24.) Holder SE, Vintiner GM. Farren B. Malcolm S, Winter RM. Confirmation of an association between RFLPs at the transforming growth factor-alpha locus and non-syndromic cleft lip and palate. J Med Genet 1992;29 (6):390-392.
(25.) Stoll C, Qian .IF, Feingold J, Sauvage P, May E. Genetic variation in transforming growth factor alpha: possible association of BamHI polymorphism with bilateral sporadic cleft lip and palate. Hum Genet 1993:92(1):81-82.
(26.) Jugessur A. Lie RT, Wilcox AJ. Murray JC. Taylor JA, Saugstad OD. et al. Cleft palate, transforming growth factor alpha gene variants, and maternal exposures: assessing gene-environment interactions in case-parent triads. Genet Epidemiol 2003;25(4):367-374.
(27.) Basart AM. Qian JF, May E. Murray JC. A PCR method for detecting polymorphism in the TGFA gene. Hum Mol Genet 1994;3(4):678.
(28.) Jara L, Blanco R. Chiffelle 1, Palomino H. Carreno H. Evidence for an association between RFLPs at the transforming growth factor alpha (locus) and nonsyndromic cleft lip/palate in a South American population. Am J Hum Genet 1995;56(1):339-341.
(29.) Jara L. Blanco R. Chiffelle I, Palomino H, Curtis D. [Cleft lip and palate in the Chilean population: association with BantH1 polymorphism of the transforming growth factor alpha (TGFA) gene]. Rev Med Chil 1993; 121(4):390-395. Spanish.
(30.) Tanabe A, Taketani S, Endo-Ichikawa Y, Tokunaga R, Ogawa Y, Hiramoto M. Analysis of the candidate genes responsible for non-syndromic cleft lip and palate in Japanese people. Clin Sci (Lond) 2000;99(2):105-111.
(31.) Vieira AR. Association between the transforming growth factor alpha gene and nonsyndromic oral clefts: a HuGE review. Am J Epidemiol 2006; 163(9):790-810.
(32.) Jawdat NG, Adnan FN, Akeel HA. Simple salting--out method for genomic DNA extraction from whole blood. Tikrit J Pure Sci 2011; 16(2):9-11
(33.) Ardinger HH, Buetow KH. Bell GI, Bardach J. Van-Demark DR, Murray JC. Association of genetic variation of the transforming growth factor-alpha gene with cleft lip and palate. Am J Hum Genet 1989;45(3):348-353.
(34.) Chenevix-Trench G, Jones K, Green AC, Duffy DL, Martin NG. Cleft lip with or without cleft palate: associations with transforming growth factor alpha and retinoic acid receptor loci. Am J Hum Genet 1992;51(6):1377-1385.
(35.) Lidral AC, Murray JC, Buetow KH. Basart AM, Schearer H, Shiang R, et al. Studies of the candidate genes TGFB2, MSX1, TGFA, and TGFB3 in the etiology of cleft lip and palate in the Philippines. Cleft Palate Craniofac J 1997;34(1):1-6.
Asghar Ebadifar , Roya Hamedi , Hamid Reza Khorram Khorshid , Kioomars Saliminejad , Koorosh Kamali , Fatemeh Aghakhani Moghadam , Nazanin Esmaeili Anvar , and Nazilla Ameli 
. Dentofacial Deformities Research Center, Research Institute of Dental Sciences, Department of Orthodontic, Faculty of Dentistry, Shahid Behehsti University of Medical Sciences, Tehran, Iran
. Department of Orthodontic, Dentofacial Deformities Research Center, Faculty of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran
. Genetic Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
. Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
. Department of Public Health, Faculty of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran
. Medical Laboratory Sciences, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
. Genetic Research Centre, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran
. Department of Orthodontic, Faculty of Dentistry, Semnan University of Medical Sciences, Semnan, Iran
* Corresponding author:
Roya Hamedi, Ph.D., Department of Orthodontic, Dentofacial Deformity Research Center, Faculty of Dentistry, Shahid Behehsti University of Medical Sciences, Tehran, Iran
Tel: +98 9125576105
Received: 5 Dec 2014
Accepted: 25 May 2015
Table 1. Primer sequences and their PCR product sizes, restriction enzymes, and RFLP fragments for the TGFA BamHI and RsaI polymorphisms Global Primer Sequence Product SNPs MAF * (5'[right arrow] 3) Size (bp) BamHI C=0.0238 F: GCCTGGCTTATTTGGGGATT 174 (rs11466297 A/C) R: AAGGGCAAGGAAACACAGG RsaI (rs3732248 A=0.2075 F: TGCCTTCCTTCTGCTATCACT 166 C/T) R: CAGAGCCAATGTCACCAAGT SNPs RFLP Fragments (bp) BamHI A allele=120+54 33 (rs11466297 A/C) C allele=174 RsaI (rs3732248 C allele=91+75 33 C/T) T allele=166 * Global Minor Allele Frequency Table 2. The genotype and allele frequencies of the TGFA BamHI and RsaI polymorphisms in nonsyndromic CL [+ or -] P patients and controls SNPs Genotype/Allele Cases (n=105) Controls (n=218) BamHI (rs11466297) AA 90 (85.7%) 207 (95.0%) AC 13 (12.4%) 11 (5.0%) CC 2 (1.9%) 0 (0.0 %) A 193 (92.0%) 425 (97.5%) C 17 (8.0%) 11 (2.5%) RsaI (rs3732248) CC 68 (64.8%) 127 (58.3%) CT 32 (30.5%) 69 (31.6%) TT 5 (4.7%) 22 (10.1%) C 168 (80.0%) 323 (74.0%) T 42 (20.0%) 113 (26.0%) SNPs Genotype/Allele p-value OR (95% CI) BamHI (rs11466297) AA Reference Genotype AC 0.016 2.1 (1 2-6.3) CC 0.187 * undefined' A Reference Allele C 0.001 3.4 (1.6-74) RsaI (rs3732248) CC Reference Genotype CT 0.582 0.87 (0.7-2.1) TT 0.090 0.42 (0.6-3.3) C Reference Allele T 0.099 0.71 (0.8-6.1) * Fisher's exact test p-value
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Original Article|
|Author:||Ebadifar, Asghar; Hamedi, Roya; Khorshid, Hamid Reza Khorram; Saliminejad, Kioomars; Kamali, Koorosh|
|Publication:||Avicenna Journal of Medical Biotechnology (AJMB)|
|Date:||Oct 1, 2015|
|Previous Article:||Interferences in the optimization of the MTT assay for viability estimation of Proteus mirabilis.|
|Next Article:||Association between serum paraoxonase 1 activities (PONase/AREase) and L55M polymorphism in risk of female infertility.|